Speaker Profile
M.D., Ph.D., Investigator, Center for Cancer Research, NCI, NIH
Biography
Dr. Udayan Guha is an Investigator in the Thoracic and Gastrointestinal Oncology Branch and head of the Cancer Signaling Networks Section at the National Cancer Institute, NIH. Dr. Guha’s scientific focus is to understand the intricate signaling networks that drive tumorigenesis and resistance to targeted treatment. He employs quantitative mass spectrometry-based proteomics to identify mutant epidermal growth factor receptor (EGFR) targets in lung cancer. He uses proteomics along with genomics technologies to interrogate the mechanisms of resistance to EGFR tyrosine kinase inhibitors (TKIs). Recently, Dr. Guha’s group has studied tumor heterogeneity and how it influences targeted treatment response using state-of-the-art proteo-genomics methodologies. He is the principal investigator of a treatment protocol to evaluate the role of local ablative therapy (LAT) and osimertinib/tagrisso treatment in patients with EGFR mutated lung adenocarcinoma. He has also established a rapid/warm autopsy protocol for Thoracic malignancies at the NIH Clinical Center.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Predicting clinical response to cancer therapies remains a major challenge in cancer treatment. Recent reports indicate that the tumor microenvironment and heterogeneity can limit the predictive power of current biomarker guided strategies. The panel will discuss new technologies that preserve these critical elements for better predictive value.
